{"name":"PAI HOLDINGS PHARM","slug":"pai-holdings-pharm","ticker":"","exchange":"","domain":"paipharm.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1985-01-01","label":"Fortaz first approved","drug":"Fortaz","drugSlug":"tazicef","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Fortaz first approved","drug":"Fortaz","drugSlug":"ceftazidime","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Fortaz","genericName":"Ceftazidime","slug":"tazicef","indication":"Bacterial infection due to Klebsiella pneumoniae","status":"marketed"},{"name":"Fortaz","genericName":"CEFTAZIDIME","slug":"ceftazidime","indication":"Lower Respiratory Tract Infections","status":"marketed"}]}],"pipeline":[{"name":"Fortaz","genericName":"Ceftazidime","slug":"tazicef","phase":"marketed","mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance.","indications":["Bacterial infection due to Klebsiella pneumoniae","Bacterial meningitis","Bacterial pneumonia","Bacterial septicemia","Bacterial urinary infection"],"catalyst":""},{"name":"Fortaz","genericName":"CEFTAZIDIME","slug":"ceftazidime","phase":"marketed","mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death.","indications":["Lower Respiratory Tract Infections","Skin and Skin-Structure Infections","Urinary Tract Infections","Bacterial Septicemia","Bone and Joint Infections"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}